<code id='B8429CF8A4'></code><style id='B8429CF8A4'></style>
    • <acronym id='B8429CF8A4'></acronym>
      <center id='B8429CF8A4'><center id='B8429CF8A4'><tfoot id='B8429CF8A4'></tfoot></center><abbr id='B8429CF8A4'><dir id='B8429CF8A4'><tfoot id='B8429CF8A4'></tfoot><noframes id='B8429CF8A4'>

    • <optgroup id='B8429CF8A4'><strike id='B8429CF8A4'><sup id='B8429CF8A4'></sup></strike><code id='B8429CF8A4'></code></optgroup>
        1. <b id='B8429CF8A4'><label id='B8429CF8A4'><select id='B8429CF8A4'><dt id='B8429CF8A4'><span id='B8429CF8A4'></span></dt></select></label></b><u id='B8429CF8A4'></u>
          <i id='B8429CF8A4'><strike id='B8429CF8A4'><tt id='B8429CF8A4'><pre id='B8429CF8A4'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:153
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Providers still hesitate to prescribe buprenorphine, study finds
          Providers still hesitate to prescribe buprenorphine, study finds

          Anurseholdstabsofbuprenorphine.EliseAmendola/APSignificantchallengesremainbeforemostAmericanclinicia

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          FDA official pushes for dedicated emerging pathogens team

          PeterMarks,directoroftheFDA'sCenterforBiologicsEvaluationandResearchGregNash/PoolviaAPWASHINGTON—Ato